A Simple-To-Use Nomogram for Predicting Early Death in Metastatic Renal Cell Carcinoma: A Population-Based Study

Tao Chen①*, Xiangpeng Zhan①*, Junfu Du②, Xiaoqiang Liu①, Wen Deng①, Shuaishuai Zhao①, Ming Jiang①, Yunqiang Xiong①, Xiaohai Zhang①, Luyao Chen①,3* and Bin Fu①,3*

① Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China, ② Department of Urology, Wuning People’s Hospital, Jiujiang, China, ③ Jiangxi Institute of Urology, Nanchang, China

OPEN ACCESS

Edited by:
Nicola Pavan, University of Trieste, Italy

Reviewed by:
Francesco Claps, The Netherlands Cancer Institute (NKI), Netherlands
Roberto Sabbatini, Ospedale Universitario di Modena, Italy

*Correspondence:
Bin Fu
urofbin@163.com
Luyao Chen
chenluyao301@163.com

† These authors have contributed equally to this work

Specialty section:
This article was submitted to Genitourinary Surgery, a section of the journal Frontiers in Surgery

Received: 08 February 2022
Accepted: 25 February 2022
Published: 22 March 2022

INTRODUCTION

Renal cell carcinoma (RCC) is derived from the abnormal differentiation of renal tubular epithelial cells, accounting for ~2–3% of adult malignant tumors (1). In the past 30 years, the incidence of RCC morbidity has been rising continuously (2). Although with the progress of diagnostic and surgical techniques, early stage RCC can be detected and resected in time, a growing number of patients are diagnosed with distant metastasis at the beginning of diagnosis (3). In addition, even nephrectomy is completed, 20% of patients will re-emerge and progress to...
mRCC (4). The prognosis of patients with metastatic renal cell carcinoma is strikingly poor and only 12% survive beyond 5 years of diagnosis (5). Due to the clinical application of molecular targeted therapies, including VEGFR, mTORC1, FGFR inhibition and anti PD-1/PD-L1 immune checkpoint inhibitors, great progress has been made on the treatment of mRCC (6). However, patients with mRCC are still vulnerable to premature death, whose reason remains to be not solved. Exploring the risk factors related to early death is instrumental for clinicians in identifying the high-risk population of early death and formulating individualized treatment to reduce the incidence of early death. However, so far, there is no in-depth study on the mortality rate of premature death in mRCC patients. Consequently, it is greatly necessary to establish a simple-to-use model to determine the risk factors leading to early death of mRCC.

The nomogram, as a useful statistical model, can integrate relevant factors to predict the individual oncologic prognosis (7). Nomograms have been extensively applied to assist medical doctors in formulating treatment plans and evaluate the prognosis of all kinds of cancers. National Comprehensive Cancer Network guidelines have introduced nomograms with excellent performance (8).

Here, our study data originated from the Surveillance, Epidemiology, and End Results (SEER) database, which is an authoritative cancer population registry in the United States collecting about 34.6% of the cancer incidence rate and survival data of the American Cancer Registry. We obtained the clinical and pathological features of mRCC and recognized risk factors to establish a practical nomogram for predicting its early death.

MATERIALS AND METHODS

Patient Cohorts
SEER® Stat software (Version 8.3.6) was applied to extracted data including demographic and clinical characteristics. In our study, patients with mRCC in the SEER database registered from 2010 to 2015 were selected. Patients enrolled in our study met the following inclusion criteria: (a) the site code was C64.9. (b) the histological codes were 8,050/3, 8,260/3, 8,310/3, 8,317/3,
FIGURE 2 | Estimation of the appropriate cut-off value for the age and tumor size by using X-tile analysis. (A,B) The optimal cut-off values of age were 61 and 78 years. (C,D) The optimal cut-off values of tumor size were 82 and 141 mm.

8,318/3, and 8,319/3. The following criteria should be excluded: (a) unknown/missing cause of death and survival month. (b) incomplete clinicopathological and demographic information including race, tumor size, N-stage, metastatic status (bone, brain, liver and lung) and T0-stage. (c) uncertain treatment information including surgery, radiotherapy or chemotherapy. Figure 1 shows the detailed screening procedure. According to previous studies, we defined early death as death within 3 months since the first diagnosis (9, 10).

The following variables were obtained: diagnostic age, gender, ethnicity, histologic type, tumor size, grade, T-stage (AJCC 7th version), N-stage (AJCC 7th version), bone, lung, liver, and brain metastasis, surgery, radiotherapy, chemotherapy, cause of death, survival months. With respect to diagnostic age and tumor size, we used the X-tile software to calculate the optimal cutoff point (Figure 2).

Nomogram Construction and Statistical Analyses
The baseline characteristics of the included population were depicted in the form of number and percentage (n, %). Univariate and multivariate logistic regression models were applied to calculate odds ratios (OR) and 95% confidence intervals (CI) to determine independent risk variables for the early death of mRCC. Then we used the connected risk factors to establish a simple-to-use nomogram for predicting the early death of mRCC. The calibration and discrimination of the model were assessed by the C-index, receiver operating characteristic curve, the area under the curve (AUC) (11) and calibration plots (12). In addition, we further evaluated the clinical utility by decision curve analysis (DCA) (13). All statistical analysis was completed by using SPSS (version 24.0; SPSS, Inc.), X-tile software, packages (rms, pROC, and rmda) in R software version 4.1.2. We considered two-tailed p-value <0.01 as statistically significance.

RESULTS
Demographic and Clinical Characteristics
6,005 patients with mRCC were included from the SEER database according the inclusion and exclusion criteria, where 1,816 patients went through early death due to all-cause death, and 1,687 patients died early from mRCC. We divided 4,203 patients into the primary dataset and 1,802 patients into the validation dataset. Among these patients who experienced premature
| Characteristic | SEER cohort (n = 6,005) | Early death (%) | No early death (%) | P-value |
|---------------|------------------------|-----------------|--------------------|---------|
| All           | 1,816 (30.2)           | 4,189 (69.8)    |                    |         |
| Age ≤61       | 575 (31.7)             | 2,052 (49.0)    | <0.001*            |         |
| 62–77         | 791 (43.6)             | 1,715 (40.9)    |                    |         |
| ≥78           | 450 (24.8)             | 422 (10.1)      |                    |         |
| Sex Male      | 1,207 (66.5)           | 2,931 (70.0)    | 0.007              |         |
| Female        | 609 (33.5)             | 1,258 (30.0)    |                    |         |
| Race White    | 1,499 (82.5)           | 3,438 (82.1)    | 0.002              |         |
| Black         | 204 (11.2)             | 397 (9.5)       |                    |         |
| Others        | 113 (6.2)              | 354 (8.5)       |                    |         |
| Histologic type ccRCC | 495 (27.3) | 2,434 (58.1) | <0.001*          |         |
| pRCC          | 66 (3.6)               | 202 (4.8)       |                    |         |
| sRCC          | 129 (7.1)              | 208 (5.0)       |                    |         |
| chRCC         | 4 (0.2)                | 37 (0.9)        |                    |         |
| cdRCC         | 15 (0.8)               | 28 (0.7)        |                    |         |
| RCC           | 1,107 (61.0)           | 1,280 (30.6)    |                    |         |
| Size ≤82      | 843 (46.4)             | 1,929 (46.0)    | 0.424              |         |
| 83–140        | 776 (42.7)             | 1,846 (44.1)    |                    |         |
| ≥141          | 197 (10.8)             | 414 (9.9)       |                    |         |
| Grade GI-II   | 100 (5.5)              | 582 (13.9)      | <0.001*            |         |
| Gill-IV       | 423 (23.3)             | 1,777 (42.4)    |                    |         |
| Unknown       | 1,293 (71.2)           | 1,830 (43.7)    |                    |         |
| T-stage T1    | 392 (21.6)             | 797 (19.0)      | <0.001*            |         |
| T2            | 391 (21.5)             | 840 (20.1)      |                    |         |
| T3            | 559 (30.8)             | 1,979 (47.2)    |                    |         |
| T4            | 250 (13.8)             | 355 (8.5)       |                    |         |
| TX            | 224 (12.3)             | 218 (5.2)       |                    |         |
| N-stage N0    | 1,033 (56.9)           | 2,901 (69.3)    | <0.001*            |         |
| N1            | 432 (23.8)             | 707 (16.9)      |                    |         |
| N2            | 351 (19.3)             | 581 (13.9)      |                    |         |
| Bone metastasis No | 1,067 (58.8) | 2,609 (62.3) | 0.010            |         |
| Yes           | 749 (41.2)             | 1,580 (37.7)    |                    |         |
| Lung metastasis No | 605 (33.3) | 1,689 (40.3) | <0.001*          |         |
| Yes           | 1,211 (66.7)           | 2,500 (59.7)    |                    |         |
| Liver metastasis No | 1,256 (69.2) | 3,589 (85.7) | <0.001*          |         |
| Yes           | 560 (30.8)             | 600 (14.3)      |                    |         |
| Brain metastasis No | 1,527 (84.1) | 3,772 (90.0) | <0.001*          |         |

(Continued)

Identifying Independent Risk Factors

In the primary cohort, we identified the risk variables associated with early death of mRCC by utilizing univariate and multivariate logistic regression analyses (Table 3). Univariate logistic models displayed age at diagnosis, race, grade, T-stage, N-stage, histologic type, metastatic sites (bone, lung, liver and brain) and treatments (surgery, radiation, and chemotherapy) were associated with early death. Multivariate analysis revealed that 11 independent risk factors related to the early death of metastatic renal cell carcinoma including age, grade, N-stage, histologic type, metastatic sites (bone, lung, liver and brain) and treatments (surgery, radiation, and chemotherapy).
TABLE 2 | Characteristics with mRCC patients in primary and validation cohort.

| Characteristics      | All patients (%) | Primary cohort (%) | Validation cohort (%) |
|----------------------|------------------|--------------------|----------------------|
|                      | All              | 6,005 (100.0)      | 4,203 (70.0)         | 1,802 (30.0)         |
| Age                  |                  |                    |                      |                     |
| ≥61                  | 2,627 (43.7)     | 1,821 (43.3)       | 806 (44.7)           |
| 62–77                | 2,506 (41.7)     | 1,768 (42.1)       | 738 (41.0)           |
| ≥78                  | 872 (14.5)       | 614 (14.8)         | 258 (14.3)           |
| Sex                  |                  |                    |                      |                     |
| Male                 | 4,138 (68.9)     | 2,888 (69.0)       | 1,240 (68.8)         |
| Female               | 1,867 (31.1)     | 1,305 (31.0)       | 562 (31.2)           |
| Race                 |                  |                    |                      |                     |
| White                | 4,937 (82.2)     | 3,485 (82.9)       | 1,452 (80.6)         |
| Black                | 601 (10.0)       | 406 (9.7)          | 195 (10.8)           |
| Other                | 467 (7.8)        | 312 (7.4)          | 155 (8.6)            |
| Histologic type      |                  |                    |                      |                     |
| ccRCC                | 2,929 (48.8)     | 2,058 (49.0)       | 871 (48.3)           |
| pRCC                 | 268 (4.5)        | 173 (4.1)          | 95 (5.3)             |
| sRCC                 | 337 (5.6)        | 235 (5.6)          | 102 (5.7)            |
| chRCC                | 41 (0.7)         | 30 (0.7)           | 11 (0.6)             |
| CDC                  | 43 (0.7)         | 34 (0.8)           | 9 (0.5)              |
| RCC                  | 2,387 (39.8)     | 1,673 (39.8)       | 714 (39.6)           |
| Size                 |                  | 0.123              |                      |
| ≤82                  | 2,772 (46.2)     | 1,946 (46.3)       | 826 (45.8)           |
| 83–140               | 2,622 (43.7)     | 1,835 (43.7)       | 787 (43.7)           |
| ≥141                 | 611 (10.2)       | 422 (10.0)         | 189 (10.5)           |
| Grade                |                  |                    |                      |                     |
| GI-II                | 682 (11.4)       | 477 (11.3)         | 205 (11.4)           |
| GIII-IV              | 2,200 (36.6)     | 1,534 (36.5)       | 666 (37.0)           |
| Unknown              | 3,123 (52.0)     | 2,192 (52.2)       | 931 (51.7)           |
| T stage              |                  |                    |                      |                     |
| T1                   | 1,189 (19.8)     | 835 (19.9)         | 354 (19.6)           |
| T2                   | 1,231 (20.5)     | 847 (20.2)         | 384 (21.3)           |
| T3                   | 2,536 (42.3)     | 1,775 (42.2)       | 763 (42.3)           |
| T4                   | 605 (10.1)       | 426 (10.1)         | 179 (9.9)            |
| TX                   | 442 (7.4)        | 320 (7.6)          | 122 (6.8)            |
| N stage              |                  |                    |                      |                     |
| N0                   | 3,934 (65.5)     | 2,789 (66.4)       | 1,145 (63.5)         |
| N1                   | 1,139 (19.0)     | 788 (18.7)         | 351 (19.5)           |
| N2                   | 932 (15.5)       | 626 (14.9)         | 306 (17.0)           |
| Bone metastasis      |                  |                    |                      |                     |
| No                   | 3,676 (61.2)     | 2,592 (81.7)       | 1,084 (60.2)         |
| Yes                  | 2,329 (38.8)     | 1,611 (18.3)       | 718 (39.8)           |
| Lung metastasis      |                  |                    |                      |                     |
| No                   | 2,294 (38.2)     | 1,618 (38.5)       | 676 (37.5)           |
| Yes                  | 3,711 (61.8)     | 2,585 (61.5)       | 1,126 (62.5)         |
| Liver metastasis     |                  |                    |                      |                     |
| No                   | 4,845 (80.7)     | 3,397 (80.8)       | 1,448 (80.4)         |
| Yes                  | 1,160 (19.3)     | 806 (19.2)         | 354 (19.6)           |
| Brain metastasis     |                  |                    |                      |                     |
| No                   | 5,299 (88.2)     | 3,732 (88.8)       | 1,567 (87.0)         |
| Yes                  | 706 (11.8)       | 471 (11.2)         | 235 (13.0)           |

TABLE 2 | Continued

| Characteristics | All patients (%) | Primary cohort (%) | Validation cohort (%) |
|-----------------|------------------|--------------------|----------------------|
| Surgery         |                  |                    |                      |
| No              | 3,383 (56.3)     | 2,356 (56.1)       | 1,027 (57.0)         |
| Yes             | 2,622 (43.7)     | 1,847 (43.9)       | 775 (43.0)           |
| Radiotherapy    |                  |                    |                      |
| No              | 4,220 (70.3)     | 2,973 (70.7)       | 1,247 (69.2)         |
| Yes             | 1,785 (29.7)     | 1,230 (29.3)       | 555 (30.8)           |
| Chemotherapy    |                  |                    |                      |
| No              | 2,918 (48.6)     | 2,084 (49.6)       | 834 (46.3)           |
| Yes             | 3,087 (51.4)     | 2,119 (50.4)       | 968 (53.7)           |

ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; sRCC, sarcomatoid renal cell carcinoma; cdRCC, collecting duct renal cell carcinoma; RCC, renal cell carcinoma.

Nomogram Construction
Significant and independent risk factors from multiple logistic regression were acquired to construct a comprehensive nomogram for predicting early death in mRCC (Figure 3). In the prediction model, surgery, chemotherapy and histological classification had great predictive value. We can predict the odds of early death of mRCC by calculating the sum of the scores of each variable.

Performance of Nomograms
In order to test our predictive model, we applied the C-index, AUC and calibration curves. The C-index of 0.842 for the predictive nomogram was detected in the primary cohort, and similar C-index was 0.863 in the validation cohort. In the primary and validation cohort, the AUC values were 0.841 (95% CI 0.828–0.854) and 0.835 (95% CI 0.814–0.855), respectively, which means an excellent discrimination capability in predicting early death of metastatic renal cell carcinoma (Figures 4A,B). Moreover, whether in the training or validation set, the solid lines of the calibration curves of both are close to 45°, which suggested the model was reliable (Figures 4C,D). Decision curve analysis (DCA) as an advanced method could evaluate the clinical efficacy of the nomogram. Our results suggested that there were excellent net benefits among most of the threshold probabilities, both in the primary cohort and in the validation cohort (Figure 5).

DISCUSSION
As the most common renal cancer, renal cell carcinoma causes a bad influence among over 400,000 individuals worldwide per year (14). Although the treatment of mRCC has made progress in the past two decades, the prognosis of patients with mRCC remains dismal (15). Previous studies on mRCC generally concentrated on the long-term survival of patients (16, 17) or risk factors related to lung and bone metastasis (18, 19). However, advanced or highly invasive tumors often lead to early death and few study has identified risk factors associated with early death in mRCC. In 2019, Shin et al. (20) constructed a model for predicting early death within...
| Variable                      | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                              | OR  | 95% CI   | P-value | OR  | 95% CI   | P-value |
| **Age (years)**              |     |          |         |     |          |         |
| ≤61                          | Ref |          |         | Ref |          |         |
| 62–77                        | 1.668 | 1.437–1.935 | <0.001* | 1.388 | 1.159–1.664 | <0.001* |
| ≥78                          | 3.474 | 2.864–4.213 | <0.001* | 1.672 | 1.306–2.140 | <0.001* |
| **Sex**                      |     |          |         |     |          |         |
| Male                         | Ref |          |         |     |          |         |
| Female                       | 1.192 | 1.036–1.372 | 0.014 |     |          |         |
| **Race**                     |     |          |         |     |          |         |
| White                        | Ref |          |         | Ref |          |         |
| Black                        | 1.337 | 1.079–1.656 | 0.008 | 1.008 | 0.773–1.314 | 0.954 |
| Other                        | 0.660 | 0.501–0.869 | 0.003 | 0.688 | 0.490–0.960 | 0.028 |
| **Histologic type**          |     |          |         |     |          |         |
| ccRCC                        | Ref |          |         | Ref |          |         |
| pRCC                         | 1.332 | 0.910–1.960 | 0.140 | 1.202 | 0.773–1.868 | 0.414 |
| sRCC                         | 3.150 | 2.366–4.194 | <0.001* | 2.806 | 1.994–3.950 | <0.001* |
| chRCC                        | 0.350 | 0.083–1.475 | 0.153 | 0.357 | 0.075–1.693 | 0.196 |
| CDC                          | 3.031 | 1.504–6.112 | 0.002 | 2.910 | 1.279–6.623 | 0.010 |
| RCC                          | 4.371 | 3.762–5.077 | <0.001* | 1.954 | 1.616–2.362 | <0.001* |
| **Size**                     |     |          |         |     |          |         |
| ≤82                          | Ref |          |         |     |          |         |
| 83–140                       | 1.017 | 0.885–1.168 | 0.816 |     |          |         |
| ≥141                         | 1.143 | 0.913–1.431 | 0.245 |     |          |         |
| **Grade**                    |     |          |         |     |          |         |
| GI-II                        | Ref |          |         | Ref |          |         |
| GIII-IV                      | 1.506 | 1.130–2.007 | 0.005 | 2.144 | 1.515–3.033 | <0.001* |
| Unknown                      | 4.360 | 3.322–5.722 | <0.001* | 1.388 | 0.996–1.935 | 0.053 |
| **T-stage**                  |     |          |         |     |          |         |
| T1                           | Ref |          |         | Ref |          |         |
| T2                           | 0.953 | 0.776–1.170 | 0.645 | 1.087 | 0.844–1.400 | 0.519 |
| T3                           | 0.612 | 0.510–0.735 | <0.001* | 1.280 | 1.001–1.636 | 0.049 |
| T4                           | 1.540 | 1.210–1.969 | <0.001* | 1.739 | 1.284–2.357 | <0.001* |
| TX                           | 2.355 | 1.810–3.064 | <0.001* | 1.479 | 1.084–2.017 | 0.014 |
| **N stage**                  |     |          |         |     |          |         |
| N0                           | Ref |          |         | Ref |          |         |
| N1                           | 1.717 | 1.454–2.028 | <0.001* | 1.365 | 1.110–1.680 | 0.003 |
| N2                           | 1.707 | 1.423–2.047 | <0.001* | 1.850 | 1.471–2.327 | <0.001* |
| **Bone metastasis**          |     |          |         |     |          |         |
| No                           | Ref |          |         | Ref |          |         |
| Yes                          | 1.097 | 0.959–1.255 | 0.177 | 1.316 | 1.088–1.591 | 0.005 |
| **Lung metastasis**          |     |          |         |     |          |         |
| No                           | Ref |          |         | Ref |          |         |
| Yes                          | 1.300 | 1.133–1.490 | <0.001* | 1.387 | 1.163–1.653 | <0.001* |
| **Liver metastasis**         |     |          |         |     |          |         |
| No                           | Ref |          |         | Ref |          |         |
| Yes                          | 2.599 | 2.219–3.043 | <0.001* | 1.989 | 1.635–2.419 | <0.001* |
| **Brain metastasis**         |     |          |         |     |          |         |
| No                           | Ref |          |         | Ref |          |         |
| Yes                          | 1.685 | 1.384–2.051 | <0.001* | 2.115 | 1.618–2.765 | <0.001* |

(Continued)
TABLE 3 | Continued

| Variable     | Univariate analysis | Multivariate analysis |
|--------------|---------------------|-----------------------|
|              | OR                  | 95% CI                | P-value |
|              |                     |                       |         |
| Surgery      | Ref                 |                       | Ref     |
|              | Yes                 | 0.146                 | 0.124–0.173 | <0.001* |
| Radiotherapy | Ref                 |                       | Ref     |
|              | Yes                 | 0.666                 | 0.573–0.774 | <0.001* |
| Chemotherapy | Ref                 |                       | Ref     |
|              | Yes                 | 0.218                 | 0.189–0.252 | <0.001* |

ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; sRCC, sarcomatoid renal cell carcinoma; cdRCC, collecting duct renal cell carcinoma; RCC, renal cell carcinoma.

The bold values mean statistically significance (p < 0.01).

FIGURE 3 | The nomogram for predicting early death in metastatic renal cell carcinoma.

1 year in patients with mRCC after first-line tyrosine kinase inhibitors (TKIs) administration. In our study, we defined it as survival ≤ 3 months according to the previous definition of early death (10, 21). The early mortality rates from all cause and cancer-specific cause for metastatic renal cell carcinoma were 30.2 and 28.1%, respectively. In addition, our subjects were not only patients treated with TKIs, but all patients with mRCC, and more patients and risk factors were included. Exploring risk
factors for early death in mRCC is beneficial, which can assist clinicians to formulate individualized treatment plans and carry out clinical trials. In addition, it is also conducive to reduce burden on patients. Because for some specific patients, they can’t benefit from treatment. Surgery may bring many side effects such as cardiovascular and cerebrovascular accidents and it is extraordinary inconvenient to go to the hospital. Consequently, we established a predictive nomogram for recognizing the early death of mRCC patients.

Previous studies had reported that demographic information such as diagnostic age, gender and race were explored to be closely associated with renal cell carcinoma (22–24). The impact of such demographic factors on early death of mRCC were evaluated in our model. But the results displayed that only age made a difference. In addition to these demographic factors, the early death of mRCC was mostly connected with clinical factors including tumor stage, histological classification, N-stage, metastatic status and treatment (surgery, chemotherapy and radiotherapy). In the era of targeted therapy for renal cell carcinoma, it is controversial whether cytoreductive nephrectomy and complete metastasectomy can bring survival benefits. In a randomized trial (CARMENA), sunitinib monotherapy was not inferior to sunitinib in the treatment of moderate to low-risk metastatic RCC after nephrectomy, which was supported by most scholars (25). However, the trial was based on MSKCC model, lacking some other relevant factors. Several retrospective studies have shown that patients with mRCC receiving targeted therapy can obtain survival benefits from nephrectomy (26–28). These analyses were limited by the nature of retrospective analysis. It should be noted that in any case, the choice of patients and the timing of surgery cause a great influence on the benefits of nephrectomy in patients with mRCC (25, 27). For patients in good condition, surgery can significantly reduce tumor burden and prolong overall survival (29). Collecting duct renal cell carcinoma (cdRCC) and sarcomatoid renal cell carcinoma (sRCC) were associated with an aggressive biology and characterized by a poor prognosis (30, 31). Consistent with previous studies, histological classification such as cdRCC and sRCC was significantly related to early death of mRCC. Metastatic renal cell carcinoma with lymph node metastasis and high-level pathological grade possessed highly aggressive and invasive characteristics, which had a negative impact on the survival of patients with mRCC (17, 32). These patients were often prone to premature death. A result from the multi-institutional registry (REMARCC) showed that different
metastatic sites had different effects on the survival benefits of patients with mRCC. The survival rate of patients with distant metastasis were often worse (33). Similar to their study, we found that patients with distant metastasis were often apt to early death, especially those with liver and brain metastasis.

The SEER database was employed in our nomogram. Thus, our analysis was based on large sample sizes, which ensured the reliability of our results. By completing curve analysis and internal verification, our model showed an excellent performance in respect of accuracy and discrimination. In addition, our nomogram was characterized by clinical practicality. As an advanced tool, DCA is different from traditional ROC analysis and can be applied to examine whether model-based clinical decisions are effective (34). Our study displayed the net benefit of our nomogram was better than that in other two scenarios (all screening or none-screening) between 10 and 90%.

Nevertheless, there were several inevitable limitations in this study that require consideration. First of all, some known relative factors were not taken into account in the nomogram. For example, the comorbidities and performance status and the Fürhman classification are thought to be related to mRCC prognosis. In addition, the number of distant metastases at
diagnosis was not explored in our study, the prognosis of mRCC patients with multiple metastases was generally poor. Secondly, our study was developed retrospectively and potential selection bias may adversely affect the conclusion. Thirdly, the detailed information on chemotherapy and specific surgical procedures were lacking in the SEER database. Fourthly, although our model was validated internally, it is necessary to carry out external verification. In the future, we need to combine with other research data to predict the early death of mRCC.

CONCLUSION

In conclusion, a comprehensive nomogram for predicting early death in metastatic renal cell carcinoma was developed according to 11 significant risk factors distinguished by univariate and multivariate logistic analysis. This nomogram is conducive for surgeons to formulate targeted treatment strategies and improve survival outcomes for patients with metastatic renal cell carcinoma.

REFERENCES

1. Zhang X, Yin X, Zhang H, Sun G, Yang Y, Chen J, et al. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer. (2019) 19:360. doi: 10.1186/s12885-019-5578-4
2. Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, et al. Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data. Med Care. (2017) 55:398–404. doi: 10.1097/MLR.0000000000000657
3. Innos K, Sepp T, Baburin A, Koitsar A, Lang K, Pärdik P, et al. Increasing kidney cancer incidence and survival in Estonia: role of age and stage. Acta Oncol. (2019) 58:21–8. doi: 10.1080/0284186X.2018.1512158
4. Shao N, Fan F, Abudurexiti M, Wang J, Zhu Y, Ye D. Causes of death and conditional survival of renal cell carcinoma. Front Oncol. (2019) 9:591. doi: 10.3389/fonc.2019.00591
5. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. (2020) 11:79–87. doi: 10.14740/wjon1279
6. de Velasco G, Bet A, Albígés L, Powles T, Rini BI, Motzer RJ, et al. Sequencing and combination of systemic therapy in metastatic renal cell carcinoma. Eur Urol Oncol. (2019) 2:505–14. doi: 10.1016/j.euro.2019.06.022
7. Zhou Y, Han H, Ruan S, Jian Z, Jin J, Zhang Y, et al. Development of a nomogram to predict disease-specific survival for patients after resection of a non-metastatic adenocarcinoma of the pancreatic body and tail. Front Oncol. (2020) 10:526602. doi: 10.3389/fonc.2020.526602
8. Hu CY, Pan ZY, Yang J, Chu XH, Zhang J, Tao XJ, et al. Nomograms for predicting long-term overall survival and cancer-specific survival in lip squamous cell carcinoma: a population-based study. Cancer Med. (2019) 8:4032–42. doi: 10.1002/cam4.2260
9. Zhu Y, Fang X, Wang L, Zhang T, Yu D, A. Predictive nomogram for early death of metastatic gastric cancer: a retrospective study in the SEER database and China. J Cancer. (2020) 11:5527–35. doi: 10.7150/jca.46563
10. Zhang Z, Pu J, Zhang H. Development and validation of a simple-to-use nomogram to predict early death in metastatic pancreatic adenocarcinoma. Front Oncol. (2021) 11:729175. doi: 10.3389/fonc.2021.729175
11. Janssens A, Martens FK. Reflection on modern methods: revisiting the area under the ROC curve. Int J Epidemiol. (2020) 49:1397–403. doi: 10.1093/ije/dy274
12. Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the hosmer-lemeshow test revisited. Crit Care Med. (2007) 35:2052–6. doi: 10.1097/01.CCM.0000275267.64078.B0
13. Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. (2018) 74:796–804. doi: 10.1016/j.euro.2018.08.038
14. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492
15. Son JY, Yoon S, Tae IH, Park YJ De U, Jeon Y, Park YJ, et al. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways. Cancer Med. (2018) 7:5083–95. doi: 10.1002/cam4.1748
16. Wei H, Miao J, Cui J, Zheng W, Chen X, Zhang Q, et al. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Sci Rep. (2021) 11:17822. doi: 10.1038/s41598-021-97365-6
17. Zheng W, Zhu W, Yu S, Li K, Ding Y, Wu Q, et al. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma. BMC Cancer. (2020) 20:1066. doi: 10.1186/s12885-020-07586-7
18. Sheng X, Lu X, Wu J, Chen L, Cao H, A. Nomogram predicting the prognosis of renal cell carcinoma patients with lung metastases. Biomed Res Int. (2021) 2021:6627562. doi: 10.1155/2021/6627562
19. Wang K, Wu Z, Wang G, Shi H, Xie J, Yin L, et al. Survival nomogram for patients with bone metastatic renal cell carcinoma: a population-based study. Int Braz J Urol. (2021) 47:333–49. doi: 10.1590/s1677-5538.ibju.2020.0195
20. Shin SJ, Kim T, Sung HH, Jeon HG, Jeong BC, Park SH, et al. Novel predictive models of early death less than 1 year in patients with metastatic renal cell carcinoma after treatment with first-line tyrosine kinase inhibitors. Clin Genitourin Cancer. (2019) 17:e1137–46. doi: 10.1016/j.clgc.2019.07.014
21. Song Z, Wang Y, Zhou Y, Zhang D, A. Novel predictive tool for determining the risk of early death from stage IV endometrial carcinoma: a large cohort study. Front Oncol. (2020) 10:620240. doi: 10.3389/fonc.2020.620240
22. Yue G, Deyu L, Lianyuan T, Fengmin S, Mei G, Yajun H, et al. Clinical and prognostic factors of patients with metastatic renal cell carcinoma stratified by age. Aging. (2021) 13:8290–305. doi: 10.18632/aging.202637
23. Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. (2008) 54:133–40. doi: 10.1016/j.euro.2007.12.001

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://seer.cancer.gov/data/.

AUTHOR CONTRIBUTIONS

TC and XZhan formulated the study. XZhan and XZhang explored and analyzed the data. YX, SZ, and MJ finished the manuscript. LC and BF proofread the manuscript. All authors approved the final version. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by the National Natural Science Foundation of P.R. China (Grant Nos. 81560419, 81960512, and 81760457) and Jiangxi Provincial Double Thousand Plan Fund Project (Grant No. jxsq2019201027).

10 March 2022 | Volume 9 | Article 871577
24. Lin J, Kamamia C, Shriver CD, Zhu K. Race and renal cell carcinoma stage at diagnosis: an analysis of the surveillance, epidemiology, and end results data. *Eur J Cancer Prev.* (2019) 28:330–4. doi: 10.1097/CEJ.0000000000000484

25. Mègean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. *N Engl J Med.* (2018) 379:417–27. doi: 10.1056/NEJMoa1803675

26. Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. *Eur Urol.* (2014) 66:704–10. doi: 10.1016/j.eururo.2014.05.034

27. Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. *J Clin Oncol.* (2016) 34:3267–75. doi: 10.1200/JCO.2016.66.7931

28. Klatte T, Fife K, Welsh SJ, Sachdeva M, Armitage JN, Aho T, et al. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. *World J Urol.* (2018) 36:417–25. doi: 10.1007/s00345-017-2154-x

29. Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, et al. Kidney cancer research network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. *Can Urol Assoc J.* (2019) 13:116–74. doi: 10.5489/cuaj.5786

30. Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. *World J Urol.* (2019) 37:115–23. doi: 10.1007/s00345-018-2355-y

31. Xiao R, Liu C, He W, Ma L. Prognostic factors and a nomogram predicting overall survival and cancer-specific survival for patients with collecting duct renal cell carcinoma. *Biomed Res Int.* (2021) 2021:6736008. doi: 10.1155/2021/6736008

32. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. *Ann Oncol.* (2011) 22:295–300. doi: 10.1093/annonc/mdq342

33. Marchioni M, Kriegmair M, Heck M, Amiel T, Porpiglia F, Ceccucci E, et al. Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. results from a multi-institutional registry (REMARCC). *Eur Urol Oncol.* (2021) 4:256–63. doi: 10.1016/j.euo.2020.12.010

34. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. *BMJ.* (2016) 352:i6. doi: 10.1136/bmj.i6

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Chen, Zhan, Du, Liu, Deng, Zhao, Jiang, Xiong, Zhang, Chen and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**